Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 151

1.

Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients.

Lee N, Maeda K, Fukizawa S, Ieiri I, Tomaru A, Akao H, Takeda K, Iwadare M, Niwa O, Masauji T, Yamane N, Kajinami K, Kusuhara H, Sugiyama Y.

Drug Metab Pharmacokinet. 2019 Aug 29. pii: S1347-4367(19)30068-0. doi: 10.1016/j.dmpk.2019.08.004. [Epub ahead of print]

PMID:
31594719
2.

Elucidation of N 1-methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters.

Miyake T, Mizuno T, Takehara I, Mochizuki T, Kimura M, Matsuki S, Irie S, Watanabe N, Kato Y, Ieiri I, Maeda K, Ando O, Kusuhara H.

Drug Metab Dispos. 2019 Nov;47(11):1270-1280. doi: 10.1124/dmd.119.087262. Epub 2019 Sep 11.

PMID:
31511257
3.

Population Pharmacokinetic Analysis of Phenytoin After Intravenous Administration of Fosphenytoin in Adult and Elderly Epileptic Patients.

Higuchi K, Yamashita D, Kashihara Y, Kakara M, Hirota T, Hirakawa M, Ieiri I.

Ther Drug Monit. 2019 Oct;41(5):674-680. doi: 10.1097/FTD.0000000000000651.

PMID:
31095070
4.

The association of tobacco use with prescription of muscle relaxants, benzodiazepines, and opioid analgesics for non-cancer pain.

Takaki H, Ieiri I, Shibuta H, Onozuka D, Hagihara A.

Am J Addict. 2019 Feb;28(2):63-70. doi: 10.1111/ajad.12830. Epub 2019 Jan 9.

PMID:
30623502
5.

Pharmacokinetics, Pharmacodynamics, and Safety of E6011, a Novel Humanized Antifractalkine (CX3CL1) Monoclonal Antibody: A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study.

Tabuchi H, Katsurabara T, Mori M, Aoyama M, Obara T, Yasuda N, Kawano T, Imai T, Ieiri I, Kumagai Y.

J Clin Pharmacol. 2019 May;59(5):688-701. doi: 10.1002/jcph.1361. Epub 2018 Dec 21.

PMID:
30575978
6.

Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers.

Mori D, Kashihara Y, Yoshikado T, Kimura M, Hirota T, Matsuki S, Maeda K, Irie S, Ieiri I, Sugiyama Y, Kusuhara H.

Drug Metab Pharmacokinet. 2019 Feb;34(1):78-86. doi: 10.1016/j.dmpk.2018.09.003. Epub 2018 Sep 20.

PMID:
30528195
7.

Efficacy of DPP-4 inhibitors, GLP-1 analogues, and SGLT2 inhibitors as add-ons to metformin monotherapy in T2DM patients: a model-based meta-analysis.

Inoue H, Tamaki Y, Kashihara Y, Muraki S, Kakara M, Hirota T, Ieiri I.

Br J Clin Pharmacol. 2019 Feb;85(2):393-402. doi: 10.1111/bcp.13807. Epub 2018 Dec 6.

PMID:
30394576
8.

Effects of magnesium oxide on pharmacokinetics of L-dopa/carbidopa and assessment of pharmacodynamic changes by a model-based simulation.

Kashihara Y, Terao Y, Yoda K, Hirota T, Kubota T, Kimura M, Matsuki S, Hirakawa M, Irie S, Ieiri I.

Eur J Clin Pharmacol. 2019 Mar;75(3):351-361. doi: 10.1007/s00228-018-2568-4. Epub 2018 Oct 31.

PMID:
30382297
9.

Characterization of changes in HbA1c in patients with and without secondary failure after metformin treatments by a population pharmacodynamic analysis using mixture models.

Tamaki Y, Maema K, Kakara M, Fukae M, Kinoshita R, Kashihara Y, Muraki S, Hirota T, Ieiri I.

Drug Metab Pharmacokinet. 2018 Dec;33(6):264-269. doi: 10.1016/j.dmpk.2018.08.002. Epub 2018 Aug 16.

PMID:
30360949
10.

Identification of drug transporters contributing to oxaliplatin-induced peripheral neuropathy.

Fujita S, Hirota T, Sakiyama R, Baba M, Ieiri I.

J Neurochem. 2019 Feb;148(3):373-385. doi: 10.1111/jnc.14607. Epub 2018 Dec 3.

PMID:
30295925
11.

Safety, Tolerability, and Pharmacokinetics of NK-104-NP.

Nakano K, Matoba T, Koga JI, Kashihara Y, Fukae M, Ieiri I, Shiramoto M, Irie S, Kishimoto J, Todaka K, Egashira K.

Int Heart J. 2018 Sep 26;59(5):1015-1025. doi: 10.1536/ihj.17-555. Epub 2018 Aug 29.

12.

Nucleosome Positioning and Gene Regulation of the SGLT2 Gene in the Renal Proximal Tubular Epithelial Cells.

Takesue H, Hirota T, Tachimura M, Tokashiki A, Ieiri I.

Mol Pharmacol. 2018 Sep;94(3):953-962. doi: 10.1124/mol.118.111807. Epub 2018 Jun 29.

PMID:
29959222
13.

Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer.

Hirota T, Muraki S, Ieiri I.

Clin Pharmacokinet. 2019 Apr;58(4):403-420. doi: 10.1007/s40262-018-0689-7. Review.

PMID:
29915924
14.

Population Pharmacokinetics and Pharmacodynamics of Oral Propranolol in Pediatric Patients With Infantile Hemangioma.

Takechi T, Kumokawa T, Kato R, Higuchi T, Kaneko T, Ieiri I.

J Clin Pharmacol. 2018 Oct;58(10):1361-1370. doi: 10.1002/jcph.1149. Epub 2018 May 10.

15.

The relationship between fine particulate matter (PM2.5) and schizophrenia severity.

Eguchi R, Onozuka D, Ikeda K, Kuroda K, Ieiri I, Hagihara A.

Int Arch Occup Environ Health. 2018 Jul;91(5):613-622. doi: 10.1007/s00420-018-1311-x. Epub 2018 Apr 23.

PMID:
29682692
16.

Interindividual Differences in the Expression of ATP-Binding Cassette and Solute Carrier Family Transporters in Human Skin: DNA Methylation Regulates Transcriptional Activity of the Human ABCC3 Gene.

Takechi T, Hirota T, Sakai T, Maeda N, Kobayashi D, Ieiri I.

Drug Metab Dispos. 2018 May;46(5):628-635. doi: 10.1124/dmd.117.079061. Epub 2018 Feb 2.

PMID:
29437875
17.

Psychological assessment of acute schizophrenia patients who experienced seclusion either alone or in combination with restraint.

Eguchi R, Onozuka D, Ikeda K, Kuroda K, Ieiri I, Hagihara A.

Int J Psychiatry Med. 2018 May;53(3):171-188. doi: 10.1177/0091217417749788. Epub 2017 Dec 27.

PMID:
29280688
18.
19.

Population Pharmacodynamic Analysis of Uric Acid-Lowering Effects of Febuxostat Based on Electronic Medical Records in Two Hospitals.

Muraki S, Moriki K, Shigematsu S, Fukae M, Kakara M, Yamashita D, Hirota T, Takane H, Shimada M, Hirakawa M, Ieiri I.

J Clin Pharmacol. 2018 Mar;58(3):304-313. doi: 10.1002/jcph.1023. Epub 2017 Oct 18.

PMID:
29045766
20.

Involvement of Organic Cation Transporters in the Kinetics of Trimethylamine N-oxide.

Miyake T, Mizuno T, Mochizuki T, Kimura M, Matsuki S, Irie S, Ieiri I, Maeda K, Kusuhara H.

J Pharm Sci. 2017 Sep;106(9):2542-2550. doi: 10.1016/j.xphs.2017.04.067. Epub 2017 May 4.

PMID:
28479364
21.

Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP.

Kashihara Y, Ieiri I, Yoshikado T, Maeda K, Fukae M, Kimura M, Hirota T, Matsuki S, Irie S, Izumi N, Kusuhara H, Sugiyama Y.

J Pharm Sci. 2017 Sep;106(9):2688-2694. doi: 10.1016/j.xphs.2017.03.010. Epub 2017 Mar 18.

PMID:
28322941
22.

Characterization of ADME gene variation in 21 populations by exome sequencing.

Hovelson DH, Xue Z, Zawistowski M, Ehm MG, Harris EC, Stocker SL, Gross AS, Jang IJ, Ieiri I, Lee JE, Cardon LR, Chissoe SL, Abecasis G, Nelson MR.

Pharmacogenet Genomics. 2017 Mar;27(3):89-100. doi: 10.1097/FPC.0000000000000260.

23.

Population pharmacokinetic-pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer.

Fukae M, Shiraishi Y, Hirota T, Sasaki Y, Yamahashi M, Takayama K, Nakanishi Y, Ieiri I.

Cancer Chemother Pharmacol. 2016 Nov;78(5):1013-1023. Epub 2016 Oct 5.

PMID:
27709284
24.

Epigenetic regulation of drug transporter expression in human tissues.

Hirota T, Tanaka T, Takesue H, Ieiri I.

Expert Opin Drug Metab Toxicol. 2017 Jan;13(1):19-30. Epub 2016 Sep 7. Review.

PMID:
27579666
25.

Circulating intestine-derived exosomal miR-328 in plasma, a possible biomarker for estimating BCRP function in the human intestines.

Gotanda K, Hirota T, Saito J, Fukae M, Egashira Y, Izumi N, Deguchi M, Kimura M, Matsuki S, Irie S, Ieiri I.

Sci Rep. 2016 Aug 30;6:32299. doi: 10.1038/srep32299.

26.

Clarification of the Mechanism of Clopidogrel-Mediated Drug-Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information.

Kim SJ, Yoshikado T, Ieiri I, Maeda K, Kimura M, Irie S, Kusuhara H, Sugiyama Y.

Drug Metab Dispos. 2016 Oct;44(10):1622-32. doi: 10.1124/dmd.116.070276. Epub 2016 Jul 25.

PMID:
27457785
27.

Population pharmacodynamic analysis of hemoglobin A1c-lowering effects by adding treatment of DPP-4 inhibitors (sitagliptin) in type 2 diabetes mellitus patients based on electronic medical records.

Kakara M, Nomura H, Ezaki M, Fukae M, Hirota T, Matsubayashi S, Hirakawa M, Ieiri I.

J Diabetes Complications. 2016 Sep-Oct;30(7):1282-6. doi: 10.1016/j.jdiacomp.2016.06.009. Epub 2016 Jun 14.

PMID:
27338508
28.

The change of pharmacokinetics of fexofenadine enantiomers through the single and simultaneous grapefruit juice ingestion.

Akamine Y, Miura M, Komori H, Tamai I, Ieiri I, Yasui-Furukori N, Uno T.

Drug Metab Pharmacokinet. 2015 Oct;30(5):352-7. doi: 10.1016/j.dmpk.2015.06.005. Epub 2015 Jun 26.

PMID:
26213156
29.

Drug-drug interactions that interfere with statin metabolism.

Hirota T, Ieiri I.

Expert Opin Drug Metab Toxicol. 2015;11(9):1435-47. doi: 10.1517/17425255.2015.1056149. Epub 2015 Jun 11. Review.

PMID:
26058399
30.

Sulfasalazine disposition in a subject with 376C>T (nonsense mutation) and 421C>A variants in the ABCG2 gene.

Gotanda K, Tokumoto T, Hirota T, Fukae M, Ieiri I.

Br J Clin Pharmacol. 2015 Nov;80(5):1236-7. doi: 10.1111/bcp.12654. Epub 2015 Jun 5. No abstract available.

31.

[Pharmacogenomics of anti-cancer drugs for individual treatment].

Ieiri I.

Nihon Rinsho. 2015 Feb;73 Suppl 2:120-5. Japanese. No abstract available.

PMID:
25831735
32.

[Pharmacokinetics and pharmacodynamics of anti-diabetic drugs--from the viewpoints of drug transporters and metabolic enzymes].

Ieiri I.

Nihon Rinsho. 2015 Mar;73(3):358-62. Review. Japanese. No abstract available.

PMID:
25812359
33.

Statin inhibits the expression of secretory phospholipase A2 and subsequent monocyte chemoattractant protein-1 in human endothelial cells.

Sonoki K, Iwase M, Ohdo S, Ieiri I, Takata Y, Kitazono T.

J Cardiovasc Pharmacol. 2014 Dec;64(6):489-96. doi: 10.1097/FJC.0000000000000147.

PMID:
25490414
34.

Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression.

Li H, Takayama K, Wang S, Shiraishi Y, Gotanda K, Harada T, Furuyama K, Iwama E, Ieiri I, Okamoto I, Nakanishi Y.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1297-305. doi: 10.1007/s00280-014-2610-x. Epub 2014 Oct 26.

35.

Neonatal Dubin-Johnson syndrome: novel compound heterozygous mutation in the ABCC2 gene.

Okada H, Kusaka T, Fuke N, Kunikata J, Kondo S, Iwase T, Nan W, Hirota T, Ieiri I, Itoh S.

Pediatr Int. 2014 Oct;56(5):e62-4. doi: 10.1111/ped.12404.

PMID:
25336012
36.

Effects of multiple-dose rifampicin 450 mg on the pharmacokinetics of fexofenadine enantiomers in Japanese volunteers.

Akamine Y, Miura M, Yasui-Furukori N, Ieiri I, Uno T.

J Clin Pharm Ther. 2015 Feb;40(1):98-103. doi: 10.1111/jcpt.12213. Epub 2014 Sep 27.

PMID:
25263393
37.

Korean, Japanese, and Chinese populations featured similar genes encoding drug-metabolizing enzymes and transporters: a DMET Plus microarray assessment.

Yi S, An H, Lee H, Lee S, Ieiri I, Lee Y, Cho JY, Hirota T, Fukae M, Yoshida K, Nagatsuka S, Kimura M, Irie S, Sugiyama Y, Shin DW, Lim KS, Chung JY, Yu KS, Jang IJ.

Pharmacogenet Genomics. 2014 Oct;24(10):477-85. doi: 10.1097/FPC.0000000000000075.

PMID:
25029633
38.

Identification and functional characterization of novel nonsynonymous variants in the human multidrug and toxin extrusion 2-K.

Nishimura K, Ide R, Hirota T, Kawazu K, Kodama S, Takesue H, Ieiri I.

Drug Metab Dispos. 2014 Sep;42(9):1432-7. doi: 10.1124/dmd.114.056887. Epub 2014 Jul 1.

PMID:
24985703
39.

Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers.

Akamine Y, Miura M, Komori H, Saito S, Kusuhara H, Tamai I, Ieiri I, Uno T, Yasui-Furukori N.

Eur J Clin Pharmacol. 2014 Sep;70(9):1087-95. doi: 10.1007/s00228-014-1705-y. Epub 2014 Jun 7.

PMID:
24903351
40.

Population pharmacodynamic analysis of LDL-cholesterol lowering effects by statins and co-medications based on electronic medical records.

Kakara M, Nomura H, Fukae M, Gotanda K, Hirota T, Matsubayashi S, Shimomura H, Hirakawa M, Ieiri I.

Br J Clin Pharmacol. 2014 Oct;78(4):824-35. doi: 10.1111/bcp.12405.

41.

Influences of artificial heart-lung machine operation on the binding sites of albumin: possibility of an effective administration plan.

Totoribe K, Takamura N, Ogata K, Tokunaga J, Kawai K, Nakamura K, Ieiri I, Higuchi S.

Int J Artif Organs. 2014 Feb;37(2):99-108. doi: 10.5301/ijao.5000299. Epub 2014 Feb 7.

PMID:
24619893
42.

Modeling and simulation of bone mineral density response from a phase 2 study of ONO-5334, a new cathepsin K inhibitor, to support dose selection in osteoporosis.

Hasegawa C, Kastrissios H, Monteleone J, Ohno T, Umemura T, Ohyama M, Nagase S, Small M, Deacon S, Ogawa M, Ieiri I.

J Clin Pharmacol. 2014 Aug;54(8):937-48. doi: 10.1002/jcph.279. Epub 2014 Feb 28.

PMID:
24615681
43.

Mechanism of the 24-hour rhythm of tumor necrosis factor-alpha formed by onset of rheumatoid arthritis.

Yoshimatsu H, Okazaki F, Ieiri I, To H.

Chronobiol Int. 2014 May;31(4):564-71. doi: 10.3109/07420528.2013.878350. Epub 2014 Feb 11.

PMID:
24517140
44.

Clinical impact of genetic variants of drug transporters in different ethnic groups within and across regions.

Ono C, Kikkawa H, Suzuki A, Suzuki M, Yamamoto Y, Ichikawa K, Fukae M, Ieiri I.

Pharmacogenomics. 2013 Nov;14(14):1745-64. doi: 10.2217/pgs.13.171. Review.

PMID:
24192123
45.

Population pharmacokinetic and pharmacodynamic modeling of different formulations of ONO-5334, cathepsin K inhibitor, in Caucasian and Japanese postmenopausal females.

Hasegawa C, Ohno T, Umemura T, Honda N, Ohyama M, Nagase S, Small M, Deacon S, Ogawa M, Ieiri I.

J Clin Pharmacol. 2014 Jan;54(1):23-34. doi: 10.1002/jcph.186. Epub 2013 Oct 10.

PMID:
24115072
46.

Association between DNA methylation in the miR-328 5'-flanking region and inter-individual differences in miR-328 and BCRP expression in human placenta.

Saito J, Hirota T, Furuta S, Kobayashi D, Takane H, Ieiri I.

PLoS One. 2013 Aug 21;8(8):e72906. doi: 10.1371/journal.pone.0072906. eCollection 2013.

47.

MicroRNA-433 negatively regulates the expression of thymidylate synthase (TYMS) responsible for 5-fluorouracil sensitivity in HeLa cells.

Gotanda K, Hirota T, Matsumoto N, Ieiri I.

BMC Cancer. 2013 Aug 2;13:369. doi: 10.1186/1471-2407-13-369.

48.

Role of methotrexate polyglutamation and reduced folate carrier 1 (RFC1) gene polymorphisms in clinical assessment indexes.

Ando Y, Shimada H, Matsumoto N, Hirota T, Oribe M, Otsuka E, Ishii K, Morimoto T, Ohashi K, Ieiri I.

Drug Metab Pharmacokinet. 2013;28(5):442-5. Epub 2013 Apr 2.

49.

Direct and rapid genotyping of SLCO1B1 388A>G and 521T>C in human blood specimens using the SmartAmp-2 method.

Yoshida K, Takano J, Ishizu Y, Lezhava A, Ieiri I, Maeda K, Hayashizaki Y, Sugiyama Y.

AAPS J. 2013 Apr;15(2):618-22. doi: 10.1208/s12248-013-9471-9. Epub 2013 Mar 8.

50.

Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs.

Ieiri I, Tsunemitsu S, Maeda K, Ando Y, Izumi N, Kimura M, Yamane N, Okuzono T, Morishita M, Kotani N, Kanda E, Deguchi M, Matsuguma K, Matsuki S, Hirota T, Irie S, Kusuhara H, Sugiyama Y.

J Clin Pharmacol. 2013 Jun;53(6):654-61. doi: 10.1002/jcph.62. Epub 2013 Feb 4.

PMID:
23381882

Supplemental Content

Support Center